MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
3.710
+0.040
+1.09%
After Hours: 3.710 0 0.00% 19:30 11/13 EST
OPEN
3.710
PREV CLOSE
3.670
HIGH
3.746
LOW
3.545
VOLUME
849.19K
TURNOVER
--
52 WEEK HIGH
8.48
52 WEEK LOW
3.350
MARKET CAP
240.27M
P/E (TTM)
-3.6104
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Reiterated as Atebimetinib’s Combination Potential and Astellas Collaboration Support $14 Price Target
TipRanks · 2d ago
Immuneering to supply atebimetinib for two Astellas pancreatic cancer studies
TipRanks · 2d ago
Astellas, Immuneering Enter Pancreatic Cancer Trial Collaboration
NASDAQ · 2d ago
Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer
Benzinga · 2d ago
Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients
Benzinga · 2d ago
Immuneering Corporation Appoints Grant C. Bogle to Board of Directors on November 9, 2026
NASDAQ · 5d ago
Immuneering Appoints Grant C. Bogle to Board of Directors
TipRanks · 5d ago
*Immuneering Appoints Grant Bogle to Bd of Directors
Dow Jones · 5d ago
More
About IMRX
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.